Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R9 - Effective November 18, 2024

Date Posted: February 10, 2025

This Billing and Coding Article has been revised under contractor numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, and NMI), and 01312 (NV).

Effective Date: November 18, 2024

Summary of Changes:

Under Article Text revised Table 1 row 11 to add "Guardant Reveal (Guardant, Inc) single Plasma Test". This revision is due to covered test that has successfully completed a TA and is effective for 11/18/2024.

Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs or access it via the CMS MCD.

Last Updated Feb 10 , 2025